REVB

Business Context and Reporting Period

Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage life science company developing the proprietary formulation Gemini to rebalance inflammation. Key product candidates include GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), and GEM-PSI (post-surgical infection).
Capital Structure Events: The Company effected a 1-for-16 reverse stock split in January 2025 and a 1-for-3 reverse stock split in July 2025. A May 2025 Public Offering raised approximately $3.4 million in net proceeds.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $6.6 million compared to the prior year period. This improvement is primarily due to the absence of a $5.9 million clinical trial settlement expense recorded in 2024 and a reduction in the change in fair value of warrant liabilities.
• Operating Expenses: Total operating expenses increased slightly by $131,681 (3.0%) year-over-year. Research and development expenses rose by $64,299, driven by increased clinical study and personnel costs, while General and Administrative expenses increased by $67,382 due to higher legal and professional fees.
• Liquidity: Cash and cash equivalents decreased by $1.3 million during the six-month period, reflecting a net cash burn of $4.7 million from operations partially offset by $3.4 million in financing proceeds from the May 2025 Public Offering.
• Deemed Dividend: A deemed dividend of approximately $3.2 million was recorded in the current period due to the down-round provision triggered by the May 2025 Public Offering, which reset the exercise prices of certain warrant classes. This reduced net loss attributable to common stockholders but had no impact on the net loss itself.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. Management does not anticipate that current cash resources ($5.2 million) will be sufficient to sustain operations for one year following the issuance of these financial statements. Additional capital is required to continue development.
• Unusual Items:
  • Deemed Dividend: $3.2 million recorded due to warrant exercise price resets.
  • Reverse Stock Splits: Two splits occurred (1-for-16 in Jan 2025; 1-for-3 in July 2025) to maintain Nasdaq listing compliance.
• Risks:
  • Regulatory Uncertainty: Significant reductions in FDA staffing may delay clinical trial reviews and marketing approvals.
  • Capital Raising: Failure to secure additional financing could force the delay or elimination of R&D programs.
  • AI Integration: Potential future reliance on AI for drug discovery carries risks regarding data quality, regulatory compliance, and third-party vendor failures.
• Outlook: The Company expects to continue incurring significant operating losses and negative cash flows for the foreseeable future as it advances clinical studies for its product candidates.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status and the $5.2 million cash balance.
• Dilution Impact: Review the terms of the May 2025 Public Offering and the subsequent down-round adjustments to warrant exercise prices, which significantly increased the number of shares issuable under Class G warrants.
• Regulatory Timeline: Assess the potential impact of FDA staffing reductions on the timelines for GEM-AKI, GEM-CKD, and GEM-PSI clinical trials.
• Expense Management: Monitor the trend in operating expenses, specifically the increase in clinical study costs, to ensure alignment with the reduced cash runway.
• Warrant Liability: Confirm the valuation methodology for the remaining warrant liabilities and the potential for future fair value adjustments impacting the income statement.